For women with genuinely low sexual desire — the kind that causes real distress — American medicine offers exactly two FDA-approved options, and they could hardly be more different. Addyi is a daily pill that works on serotonin. PT-141 (Vyleesi) is an as-needed injection that works on melanocortin receptors. Choosing between them is less about which is “better” and more about which fits your life, your health profile, and honestly, your relationship with alcohol. Here is the head-to-head.
The Comparison at a Glance
| PT-141 (Vyleesi) | Addyi (flibanserin) | |
|---|---|---|
| Approved | 2019 | 2015 (first HSDD drug) |
| How taken | Injection, as needed, 45+ min before intimacy | Pill, every night at bedtime |
| Mechanism | Melanocortin receptors (desire circuitry) | Serotonin receptors (originally an antidepressant candidate) |
| Usage limits | Max 1 dose/24 hrs; max 8/month | Daily, whether or not intimacy is planned |
| Onset pattern | Per-dose, same evening | Builds over weeks of daily use |
| Alcohol | No problematic interaction shown in studies | The famous issue: risk of severe low blood pressure and fainting; label advises separating alcohol from the bedtime dose |
| Signature side effects | Nausea, flushing, temporary BP rise, rare lasting skin darkening | Dizziness, sleepiness, fatigue, low blood pressure, fainting |
| Cardiovascular note | Not recommended with uncontrolled hypertension | Contraindicated with certain liver problems and interacting drugs (CYP3A4 inhibitors) |
| Approved for | Premenopausal acquired, generalized HSDD | Premenopausal acquired, generalized HSDD |
The Lifestyle Question Usually Decides It
Strip away the pharmacology and the practical fork is simple. Addyi asks for a nightly commitment — a pill every bedtime, indefinitely, with effects that accumulate gradually and an alcohol constraint woven into your evenings. PT-141 asks for tolerance of an injection and a little planning — a dose on the evenings that matter, at most eight times a month. Women who dislike daily medication or drink wine with dinner tend to land on PT-141; women who want desire addressed continuously in the background, and who would rather never see a needle, tend toward Addyi. Neither preference is wrong.
The Honest Efficacy Conversation
Neither drug produced dramatic numbers in trials — both showed modest, statistically significant improvements over placebo in desire scores and distress, in overlapping but not identical measures, and they have never been compared head-to-head in a trial. Meaningful minorities of women respond well to each; many respond to neither; and some who fail one respond to the other, which is why insurance plans sometimes require trying Addyi before covering Vyleesi. Both labels build in the same honesty mechanism: reassess at eight weeks and stop if it isn’t helping.
Side-Effect Profiles: Pick Your Trade-Off
PT-141’s issues cluster around each dose: nausea (the most common complaint), flushing, a temporary blood-pressure bump, and — with overuse, particularly in darker skin tones — the possibility of focal skin darkening that may not fully fade. Addyi’s issues are the daily kind: next-day grogginess, dizziness, fatigue, and the low-blood-pressure risk that made its alcohol interaction famous. A useful way to frame it: PT-141’s side effects visit occasionally; Addyi’s move in.
Where the "Aphrodisiac Peptide" Framing Goes Wrong
PT-141 sometimes gets marketed as an aphrodisiac, which overpromises what the data show. Neither of these drugs creates desire on command in women who don’t have HSDD — they were studied in, and approved for, women with a diagnosed desire disorder causing distress. If desire has dropped and it bothers you, the productive first step is a real workup (hormones, medications, sleep, relationship context), because low desire with an identifiable cause has better-targeted fixes. Our guides to peptides for libido in women and the sexual wellness hub cover the wider landscape, and the complete PT-141 guide goes deeper on the injection option.